Alex Gorsky, Johnson & Johnson

Chairman and CEO, Johnson & Johnson
Total 2014 Compensation: $24.99 million

Alex Gorsky got a big lift in pay for 2014, moving from $16.9 million in 2013 to just shy of $25 million. Some accounting changes did represent part of that increase, but not all of it--and Johnson & Johnson's ($JNJ) financials show why.

J&J has been among the few drugmakers with little to apologize about when totting up new product sales. The company's pharma business has been growing fast, thanks to prostate cancer pill Zytiga, blood cancer therapy Imbruvica, anticoagulant Xarelto and diabetes med Invokana, to name a few.

Thanks to all that--and some growth from top-selling Remicade, too--the company racked up a 16% increase in pharma sales last year. Its consumer health division finally moved out of the woods, with more products back on the shelves after the long series of recalls back in 2009. Overall, the company managed a 4.2% increase in sales.

J&J isn't all golden, however. The company is still embroiled in litigation over alleged failures to warn about side effects of products such as the antipsychotic drug Risperdal and its vaginal mesh devices. But despite legal settlements and the like, J&J still delivered big for shareholders, with returns of 17% for 2014, the company's proxy points out.

Gorsky's salary is about on par with those of his pharma peers at $1.5 million, and he doesn't collect any straight bonus pay. Incentive pay ticked slightly above $5 million, a 3% increase over 2013's $4.87 million. The big differences over 2013 came in stock awards--$9.47 million, up from $5.99 million--and options, which amounted to $4.17 million, up from $2.67 million. Plus, Gorsky saw his pension and deferred compensation grow by $4.6 million, more than twice the increase recorded for 2013. Total: $24.99 million.

For more:
Special Report: Top 15 highest-paid biopharma CEOs of 2013 - Alex Gorsky, J&J
J&J's global hunt for new drugs, cool new tech spurs 17 new deals
J&J promises new uses for old meds to keep pharma sales flying high
Currency hurts, Olysio plummets, but J&J pharma growth carries on
Why didn't J&J buy Imbruvica partner Pharmacyclics? It wants hot drugs cheap, CEO says
J&J boosts CEO pay to $25M, doubles R&D chief's haul
J&J loses first court battle over Risperdal's breast-growth side effects

Alex Gorsky, Johnson & Johnson
Read more on

Suggested Articles

At one point, Novartis even offered up $90 apiece for the inclisiran developer but would later say even $85 was too much, a securities filing shows.

Sanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab.

After more than 10 years as partners, Sanofi and Regeneron are splitting up their deal to comarket PCSK9 med Praluent and immunology drug Kevzara.